Transporters in Drug Development: Scientific and Regulatory Considerations | Zendy

Zhang Lei | Zendy; Huang ShiewMei | Zendy; Reynolds Kellie | Zendy; Madabushi Rajanikanth | Zendy; Zineh Issam | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Transporters in Drug Development: Scientific and Regulatory Considerations

Author(s) -

Zhang Lei,

Huang ShiewMei,

Reynolds Kellie,

Madabushi Rajanikanth,

Zineh Issam

Publication year - 2018

Publication title -

clinical pharmacology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.941

H-Index - 188

eISSN - 1532-6535

pISSN - 0009-9236

DOI - 10.1002/cpt.1214

Subject(s) - drug development , drug , clinical pharmacology , engineering ethics , pharmacology , medicine , engineering

Transporters can affect a drug's pharmacokinetics (PK) by controlling absorption, distribution, and elimination processes. They can also affect a drug's pharmacodynamics (PD) by influencing its access to the site of action. More recently, transporters have become important as drug targets (e.g., urate transporter inhibitors as treatment for gout and sodium/glucose cotransporter-2 inhibitors for treating type 2 diabetes). As such, it is important to consider the role of transporters during drug development.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research